Results of a phase I/II trial adding carmustine (300 mg/m2) to melphalan (200 mg/m2) in multiple myeloma patients undergoing autologous stem cell transplantation

✍ Scribed by Comenzo, R L; Hassoun, H; Kewalramani, T; Klimek, V; Dhodapkar, M; Reich, L; Teruya-Feldstein, J; Fleisher, M; Filippa, D; Nimer, S D

• Book ID: 110056524
• Publisher: Nature Publishing Group
• Year: 2005
• Tongue: English
• Weight: 128 KB
• Volume: 20
• Category: Article
• ISSN: 0887-6924
• DOI: 10.1038/sj.leu.2404003